Bayer will not accept a ruling by the Intellectual Property Appellate Board in Chennai on Monday, upholding the compulsory licence granted on March 9 last year and it will appeal against the patent office order at the high court in Mumbai, a spokesperson told PTI.
The drug Glivec was a genuinely new and important discovery deserving of patent protection.
On Monday, the Appellate Board upheld the compulsory licence granted to domestic firm Natco Pharma last year, against Bayer's patented anti-cancer drug Nexavar.
To some -- especially western drug companies -- he is a 'pirate'. To others, mostly those in developing countries, he is an unparalleled hero. Either way, Yusuf Hamied, 75, is perhaps the most talked about man in pharmaceutical circles in the last decade.
Court rejects bid to introduce a linkage between regulatory approval of a medicine and its patent status.
So vaccinate employees and families, staff at home, rickshaw drivers, milkmen, service providers, shopkeepers and street vendors, says Naushad Forbes.
Services attracted the most FDI during the first eleven months period of 2015-16.
Delegation visit ahead of patent law report.
The USTR has placed India on its "priority watch" list for two years in a row, saying the country's patent laws unfairly favour local drug makers.
Investors indulged in profit booking at attractive and higher valuations
The Supreme Court had rejected the company's plea for a patent on cancer drug Glivec in April.
The United States 'is leading the world in the use of compulsory licenses, and is hypocritical in voicing indignance when developing countries issue compulsory licenses for essential drugs,' Washington-based Knowledge Ecology International, with its offices in Geneva, has alleged.
India had been engaged in a contentious battle with the US over the issue, especially in the pharmaceutical sector.
Indian firm to soon launch copycat of anti-breast-cancer drug.
Special 301 Report expresses concern over weak IPR laws, to conduct reviews.
India's IPR framework and enforcement were comparable to those in developed countries
The unilateral pressure by US administration on India, at the behest of US Business Associations lobby through US International Trade Commission investigations and request to USTR to enlist India under Priority Foreign Country under Special 301 review, lacks legitimacy under WTO framework, the signatories to the letter said.
Details on prices sought as 10 generic drugs become up to 83 times costlier in 6 months
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances